MedicaidPrior AuthMedium impact
Beleodaq® (belinostat) (New)
Humana·OH · Oncology, Hematology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Ohio has implemented a new prior authorization policy for Beleodaq (belinostat), a cancer medication used to treat relapsed or refractory peripheral T-cell lymphoma. The policy requires prior authorization with specific medical criteria and excludes patients with disease progression or certain concurrent medications.
Action Required
Before January 1, 2026: Billing team must update prior authorization processes for Beleodaq (belinostat) IV solution for Humana Medicaid Ohio members. Providers must obtain prior authorization by documenting diagnosis of relapsed or refractory peripheral T-cell lymphoma and confirming patient has not progressed on Beleodaq or is not on concurrent Istodax, Zolinza, or Folotyn therapy. Update encounter forms and EMR templates to include these requirements. Claims without prior authorization will be denied.